title: Treatments for osteoporosis in people with a disability.
abstract: The morbidity from osteoporotic fractures for people with a disability is considerable because of the increased risk of medical complications, loss of independence and mobility, and prolonged hospitalization. The frequency with which low bone mineral density occurs in people with a disability is now well recognized, and professionals have a greater awareness of the need to investigate bone mineral density levels with a view to preventing fragility fractures. After patients with osteoporosis are identified, the challenge is to treat them appropriately. This article reviews the physical and pharmacologic measures that have been researched in the prevention and treatment of low bone mineral density in people with a disability.
authors.affiliation: Department of Rehabilitation Medicine (Spinal Cord Systems of Care), National Rehabilitation Hospital, Rochestown Ave, Dún Laoghaire, Co. Dublin, Ireland. eimear.smith@nrh.ie
authors.forename: Eimear M
authors.initials: EM
authors.lastname: Smith
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006233:Persons with Disabilities; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy; D000068296:Risedronic Acid; D013119:Spinal Cord Injuries / Q000453:epidemiology; D020521:Stroke / Q000453:epidemiology / Q000503:physiopathology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid